| All population | Followed "when-to-start" guidelines | Followed "what-to-start" guidelines | ||||
---|---|---|---|---|---|---|---|
Characteristic | N = 1,365 | Yes (n = 1,214) | No (n = 151) | P | Yes (n = 1,215) | No (n = 150) | P |
Male (%) | 69.7 | 68.6 | 78.2 | 0.02 | 68.7 | 77.3 | 0.03 |
Median Age (years) | 37.3 | 37.5 | 34.7 | 0.002 | 37.1 | 38.5 | - |
MSM (%) | 41.4 | 39.0 | 60.9 | <0.001 | 41.1 | 44.0 | - |
HBV/HCV coinfection (%) | 13.1 | 13.3 | 11.3 | - | 13.2 | 12.7 | - |
CDC stage C (%) | 22.6 | 25.4 | 0 | <0.001 | 20.2 | 41.3 | <0.001 |
Median CD4 (/mm3) | 248 | 230 | 513 | <0.001 | 256 | 182 | <0.001 |
Median HIV-RNA (log cps/mL) | 4.8 | 4.8 | 4.4 | <0.001 | 4.7 | 4.9 | <0.001 |
HIV-RNA >105 copies/mL (%) | 40.5 | 41.4 | 14.3 | <0.0001 | 37.3 | 48.2 | <0.0001 |